Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer

Oncotarget

Volumn 7, Issue 42, 2016, Pages 68749-68767

  Moench, Romana ^a   Grimmig, Tanja ^a   Kannen, Vinicius ^b   Tripathi, Sudipta ^c   Faber, Marc ^a   Moll, Eva Maria ^a   Chandraker, Anil ^c   Lissner, Reinhard ^a   Germer, Christoph Thomas ^a   Waaga Gasser, Ana Maria ^a,c   Gasser, Martin ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Colorectal cancer; Glucose metabolism; MAPK pathway; PDGF; PI3K Akt mTOR

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; VASCULOTROPIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ADULT; AKT SIGNALING; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; COLON CANCER CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MAPK SIGNALING; OXIDATION; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; COLORECTAL TUMOR; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GLYCOLYSIS; HCT116 CELLS; HT29 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85028530039     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.11899     Document Type: Article

References (55)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine. 2004; 350:2335-2342
2. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of clinical oncology. 2007; 25:1539-1544
3. Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptorexpressing tumours. Expert opinion on pharmacotherapy. 2004; 5:1621-1633
4. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nature biotechnology. 2007; 25:1134-1143
5. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381:303-312
6. Lindberg N, Holland EC. PDGF in gliomas: more than just a growth factor? Upsala journal of medical sciences. 2012; 117:92-98
7. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiological reviews. 1999; 79:1283-1316
8. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and molecular biology reviews. 2011; 75:50-83
9. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochemical Society transactions. 2012; 40:139-146
10. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3KmTOR pathways: cross-talk and compensation. Trends in biochemical sciences. 2011; 36:320-328
11. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149:274-293
12. Morrison DK. MAP kinase pathways. Cold Spring Harbor perspectives in biology. 2012; 4
13. Sebolt-Leopold JS, Herrera R. Targeting the mitogenactivated protein kinase cascade to treat cancer. Nature reviews Cancer. 2004; 4:937-947
14. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature reviews Cancer. 2008; 8:705-713
15. Unwith S, Zhao H, Hennah L, Ma D. The potential role of HIF on tumour progression and dissemination. International journal of cancer. 2014
16. Jones NP, Schulze A. Targeting cancer metabolism-aiming at a tumour's sweet-spot. Drug discovery today. 2012; 17:232-241
17. Parks SK, Chiche J, Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nature reviews Cancer. 2013; 13:611-623
18. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET, Cance WG. Receptor tyrosine kinases expressed in metastatic colon cancer. International journal of cancer. 1995; 60:791-797
19. Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K, Gerdin B. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Laboratory investigation. 1993; 69:682-689
20. Raica M, Cimpean AM. Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy. Pharmaceuticals. 2010; 3:572-599
21. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR, Fidler IJ. Expression of activated plateletderived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. International journal of cancer. 2006; 119:2567-2574
22. Heldin CH. Autocrine PDGF stimulation in malignancies. Upsala journal of medical sciences. 2012; 117:83-91
23. Gordon GM, Du W. Conserved RB functions in development and tumor suppression. Protein & cell. 2011; 2:864-878
24. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis. 2000; 21:857-864
25. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes & development. 1999; 13:1422-1437
26. De Benedetti A, GraffJR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004; 23:3189-3199
27. GraffJR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer research. 2008; 68:631-634
28. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. The lancet oncology. 2005; 6:322-327
29. Yuge R, Kitadai Y, Shinagawa K, Onoyama M, Tanaka S, Yasui W, Chayama K. mTOR and PDGF pathway blockade inhibits liver metastasis of colorectal cancer by modulating the tumor microenvironment. The American journal of pathology. 2015; 185:399-408
30. Pennock S, Kazlauskas A. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Molecular and cellular biology. 2012; 32:1955-1966
31. van den Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. Nature reviews Molecular cell biology. 2008; 9:713-724
32. Kaulfuss S, Seemann H, Kampe R, Meyer J, Dressel R, Konig B, Scharf JG, Burfeind P. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells. Oncotarget. 2013; 4:1037-1049. doi: 10.18632/oncotarget.1085
33. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003; 17:590-603
34. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harbor perspectives in biology. 2012; 4:a011189
35. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. Journal of nuclear medicine. 2011; 52:497-500
36. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013; 2:e71
37. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of cellular physiology. 2005; 202:654-662
38. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature reviews Cancer. 2011; 11:85-95
39. Arseneault R, Chien A, Newington JT, Rappon T, Harris R, Cumming RC. Attenuation of LDHA expression in cancer cells leads to redox-dependent alterations in cytoskeletal structure and cell migration. Cancer letters. 2013; 338:255-266
40. Markert CL. Lactate dehydrogenase. Biochemistry and function of lactate dehydrogenase. Cell biochemistry and function. 1984; 2:131-134
41. Gotanda Y, Akagi Y, Kawahara A, Kinugasa T, Yoshida T, Ryu Y, Shiratsuchi I, Kage M, Shirouzu K. Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor. Anticancer research. 2013; 33:2941-2947
42. Samudio I, Fiegl M, AndreeffM. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer research. 2009; 69:2163-2166
43. Fogg VC, Lanning NJ, Mackeigan JP. Mitochondria in cancer: at the crossroads of life and death. Chinese journal of cancer. 2011; 30:526-539
44. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxiainducible factor 1 and cAMP response elements. The Journal of biological chemistry. 1995; 270:21021-21027
45. Dang CV. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Foundation symposium proceedings. 2007; 35-53
46. Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Molecular cancer therapeutics. 2007; 6:732-741
47. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. Journal of molecular medicine (Berlin, Germany). 2007; 85:1301-1307
48. Wu XY, Fu ZX, Wang XH. Effect of hypoxia-inducible factor 1-alpha on Survivin in colorectal cancer. Molecular medicine reports. 2010; 3:409-415
49. Bhalla S, Evens AM, Prachand S, Schumacker PT, Gordon LI. Paradoxical regulation of hypoxia inducible factor-1alpha (HIF-1alpha) by histone deacetylase inhibitor in diffuse large B-cell lymphoma. PloS one. 2013; 8:e81333
50. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clinical cancer research. 2009; 15:6479-6483
51. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer cell. 2007; 12:108-113
52. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nature reviews Cancer. 2008; 8:976-990
53. Podar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell cycle (Georgetown, Tex). 2010; 9:1722-1728
54. Garber K. Energy deregulation: licensing tumors to grow. Science (New York, NY). 2006; 312:1158-1159
55. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94:6658-6663